查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587661

2030年甲状腺疾病治疗市场预测：依疾病类型、治疗类型、给药途径、药物类型、通路和地区进行全球分析

Thyroid Gland Disorders Treatment Market Forecasts to 2030 - Global Analysis By Type of Disorder, Treatment Type, Route of Administration, Drug Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球甲状腺疾病治疗市场规模为 25 亿美元，预计 2030 年将达到 36.9 亿美元，预测期内复合年增长率为 6.7%。

甲状腺疾病治疗是指旨在控制影响甲状腺的疾病的医疗干预措施。常见的甲状腺疾病包括甲状腺机能低下症（甲状腺机能低下症）、甲状腺功能亢进（hyperthymosis）、甲状腺结节、甲状腺癌等。治疗方法因疾病而异，包括荷尔蒙补充疗法、抗甲状腺药物、放射性碘和手术。

根据加拿大癌症协会的2022年报告，2022年将有近6,700名加拿大人被诊断出罹患甲状腺癌。

甲状腺疾病增加

甲状腺疾病盛行率的上升和人们对甲状腺健康意识的提高，加上诊断技术的进步，将导致早期发现和早期治疗。患者数量的增加推动了对有效治疗的需求，包括药物治疗、放射性碘治疗和手术干预。此外，肥胖和自体免疫疾病等危险因子的普遍存在进一步加剧了市场的成长。因此，製药公司正在增加研发投资，以提供创新的治疗方法。

昂贵的治疗费用

治疗甲状腺疾病的高成本限制了患者获得必要的治疗，这严重阻碍了市场的成长。许多患者可能因经济困难而放弃或推迟治疗，导致健康状况恶化。此外，保险范围有时不足，进一步加剧了财务问题。这种情况阻碍了製药公司投资新治疗方法，并减少了市场的创新和竞争。结果，治疗的整体有效性下降，影响患者的治疗结果，增加医疗保健系统的负担，并阻碍市场成长。

伙伴关係与联合研究

甲状腺疾病治疗市场的联盟与合作将加强研究和开发，并促进製药公司、医疗保健提供者和研究机构之间的专业知识和资源共用。这些合作加速了药物开发的创新和先进治疗方法的引入，以改善患者的治疗效果。协作努力还可以带来更有效的行销策略，提高治疗方法的认识和可及性。此外，伙伴关係关係加速了临床试验，缩短了新治疗方法的上市时间，协助获得监管部门的核准，并最终推动市场成长。

激烈的竞争

甲状腺疾病治疗市场的激烈竞争可能会压低价格并降低製造商的利润率，从而阻碍成长。公司可能会在行销和促销方面投入大量资金以获得市场占有率，从而导致营运成本增加。此外，专注于将自己与竞争对手区分开来可能会耗尽研发资源，并阻碍治疗方案的创新。由于公司将短期利润置于长期进步之上，患者获得尖端治疗方法的机会可能有限，最终影响整体市场成长和患者治疗结果。

COVID-19 的影响

COVID-19 大流行扰乱了医疗保健服务、延迟了诊断并限制了常规护理的获得，从而影响了甲状腺疾病的治疗。甲状腺疾病患者，特别是那些需要定期监测或手术的患者，由于医疗系统负担过重而面临治疗延误。远端医疗已经成为一种解决方案，可以进行远距咨询和管理。此外，COVID-19 对免疫系统的影响与甲状腺发炎（甲状腺炎）之间的关联引起了人们对病毒可能引起的甲状腺功能障碍的担忧，并影响了大流行期间和大流行后的治疗方法。

预计药物治疗领域在预测期内将是最大的。

在预测期内，由于管理常见甲状腺疾病的非侵入性解决方案，药物治疗领域预计将创下最大的市场占有率。甲状腺机能低下症通常用于治疗甲状腺功能减退症，以替代缺失的激素，而甲硫咪唑和丙硫氧嘧啶等抗甲状腺药物则透过抑制过量的激素产生来治疗甲状腺功能亢进。这些药物可以提供长期的疾病控制，并且通常可以延迟或避免手术或放射性碘治疗的需要。

在预测期内，注射剂领域的复合年增长率最高。

在预测期内，注射剂领域预计将以最高复合年增长率成长。这是因为其有效且有针对性的治疗选择，特别是对于患有严重甲状腺功能障碍的患者。甲状腺激素注射和生技药品等注射治疗可以快速缓解甲状腺机能低下症和甲状腺相关紧急情况等病症。由于可以施用精确的剂量，因此可以比内服药物更可靠地控制甲状腺激素水平。注射剂的日益普及、药物配方的进步以及甲状腺疾病盛行率的增加都促进了这一领域的成长。

比最大的地区

在估计期间，由于人们对甲状腺疾病的认识不断提高以及医疗技术的进步，预计亚太地区将占据最大的市场占有率。主要治疗方法包括荷尔蒙替代疗法、抗甲状腺药物和手术介入。由于患者人数的增加和医疗基础设施的改善，印度和中国等国家正在经历显着的成长。此外，政府促进甲状腺健康的措施和越来越多地采用远端医疗正在进一步推动市场成长。

复合年增长率最高的地区：

由于甲状腺相关疾病（包括甲状腺机能低下症和甲状腺功能亢进症）的盛行率不断上升，预计北美地区在预测期内将实现最高的复合年增长率。诊断技术的进步和标靶治疗的不断采用正在促进市场扩张。此外，医疗保健专业人员和患者对甲状腺疾病的认识不断提高，推动了对有效治疗的需求，包括荷尔蒙补充疗法和手术选择。此外，主要市场参与者的存在和对创新治疗方法的不断探索预计将进一步增强该地区的市场活力。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球甲状腺疾病治疗市场：依疾病类型

  • 甲状腺机能低下症
  • 甲状腺功能亢进症
  • 甲状腺肿
  • 甲状腺癌
  • 桥本氏症
  • 格雷夫兹病
  • 甲状腺结节
  • 其他疾病类型

第六章全球甲状腺疾病治疗市场：依治疗类型

  • 药品
    • 荷尔蒙补充疗法
    • 抗甲状腺药物
    • 放射性碘治疗
  • 外科手术
    • 甲状腺切除术
    • 切除术
  • 射频消融术
  • 其他治疗类型
    • 食品补充品
    • 草药疗法

第七章全球甲状腺疾病治疗市场：依给药途径

  • 口服
  • 注射
  • 外用
  • 其他给药途径

第八章全球甲状腺疾病治疗市场：依药物类型

  • 左旋甲状腺素
  • 三碘甲状腺胺酸
  • 丙硫氧嘧啶
  • 咪唑类化合物
  • 其他药物类型

第九章全球甲状腺疾病治疗市场：依通路分类

  • 医院药房
  • 零售药房
  • 网路药房
  • 诊所
  • 其他分销管道

第十章全球甲状腺疾病治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 公司概况

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • ThyroSafe, LLC
  • Hormone Health Network
  • Zydus Cadila
  • Mylan NV
  • Hikma Pharmaceuticals PLC
  • Endo International PLC
  • Genzyme Corporatio
  • Roche Holding AG
Product Code: SMRC27646

According to Stratistics MRC, the Global Thyroid Gland Disorders Treatment Market is accounted for $2.50 billion in 2024 and is expected to reach $3.69 billion by 2030 growing at a CAGR of 6.7% during the forecast period. Thyroid gland disorders treatment refers to medical interventions aimed at managing conditions that affect the thyroid, a small gland in the neck responsible for regulating metabolism. Common thyroid disorders include hypothyroidism (underactive thyroid), hyperthyroidism (overactive thyroid), thyroid nodules, and thyroid cancer. Treatment options vary based on the disorder and may include hormone replacement therapy, anti-thyroid medications, radioactive iodine, or surgery.

According to the Canadian Cancer Society 2022 report, close to 6,700 Canadians were diagnosed with thyroid cancer in the year 2022.

Market Dynamics:

Driver:

Rising incidence of thyroid disorders

The rising incidence of thyroid disorders and increasing awareness of thyroid health, coupled with advancements in diagnostic technologies, leads to earlier detection and treatment. This growing patient population drives demand for effective therapies, including medications, radioactive iodine therapy, and surgical interventions. Additionally, the prevalence of risk factors such as obesity and autoimmune diseases further escalates the market's growth. Consequently, pharmaceutical companies are increasingly investing in research and development to offer innovative treatment options.

Restraint:

High cost of treatments

The high cost of treatments for thyroid gland disorders significantly hinders market growth by limiting patient access to necessary therapies. Many individuals may forgo or delay treatment due to financial constraints, leading to worsening health conditions. Additionally, insurance coverage can be inadequate, further exacerbating affordability issues. This situation discourages pharmaceutical companies from investing in new therapies, reducing innovation and competition in the market. Consequently, the overall treatment landscape becomes less effective, impacting patient outcomes and increasing the burden on healthcare systems, thus hindering the growth of the market.

Opportunity:

Partnerships and collaborations

Partnerships and collaborations in the thyroid gland disorders treatment market enhance research and development, facilitating the sharing of expertise and resources among pharmaceutical companies, healthcare providers, and research institutions. These alliances foster innovation in drug development and the introduction of advanced treatment modalities, improving patient outcomes. Collaborative efforts can also lead to more effective marketing strategies, increasing awareness and accessibility of therapies. Furthermore, partnerships can accelerate clinical trials, shorten time-to-market for new treatments, and help in obtaining regulatory approvals, ultimately propelling market growth.

Threat:

Intense competition

Intense competition in the thyroid gland disorders treatment market can hinder growth by driving down prices, which may reduce profit margins for manufacturers. Companies may invest heavily in marketing and promotions to gain market share, leading to increased operational costs. Additionally, the focus on competitive differentiation can divert resources from research and development, stalling innovation in treatment options. As companies prioritize short-term gains over long-term advancements, patients may face limited access to cutting-edge therapies, ultimately impacting overall market growth and patient outcomes.

Covid-19 Impact

The COVID-19 pandemic impacted thyroid gland disorders treatment by disrupting healthcare services, delaying diagnoses, and limiting access to routine care. Patients with thyroid disorders, especially those requiring regular monitoring or surgery, face postponements due to overwhelmed healthcare systems. Telemedicine emerged as a solution, enabling remote consultations and management. Additionally, COVID-19's effects on the immune system and its association with thyroid inflammation (thyroiditis) increased concerns about potential virus-induced thyroid dysfunction, influencing treatment approaches during and after the pandemic.

The medications segment is expected to be the largest during the forecast period

During the forecast period, the medications segment is anticipated to register the largest market share, due to non-invasive solutions for managing common thyroid conditions. For hypothyroidism, levothyroxine is widely prescribed to replace deficient hormones, while antithyroid drugs like methimazole and propylthiouracil treat hyperthyroidism by reducing excessive hormone production. These medications provide long-term disease management, often delaying or preventing the need for surgery or radioactive iodine therapy.

The injectable segment is expected to have the highest CAGR during the forecast period

During the projection period, the injectable segment is expected to grow at the highest CAGR, due to efficient and targeted treatment options, especially for patients with severe thyroid dysfunction. Injectable treatments, such as thyroid hormone injections or biologics, provide rapid relief in conditions like hypothyroidism or thyroid-related emergencies. Their effectiveness in delivering precise doses ensures better control of thyroid hormone levels compared to oral medications. The growing adoption of injectables, advancements in drug formulations, and the increasing prevalence of thyroid disorders contribute to the segment's growth.

Region with largest share:

During the estimation period, the Asia Pacific region is expected to capture the largest market share due to raised awareness of thyroid diseases and advancements in medical technology. Key therapies include hormone replacement treatments, antithyroid medications, and surgical interventions. Countries like India and China are witnessing significant growth driven by a growing patient population and enhanced healthcare infrastructure. Moreover, government initiatives promoting thyroid health and the rising adoption of telemedicine are further propelling market growth.

Region with highest CAGR:

The North America region is projected to achieve the highest CAGR during the forecast period, due to the rising prevalence of thyroid-related conditions, including hypothyroidism and hyperthyroidism. Advances in diagnostic technologies and the increasing adoption of targeted therapies contribute to market expansion. Additionally, the growing awareness of thyroid disorders among healthcare professionals and patients drives demand for effective treatments, including hormone replacement therapies and surgical options. Moreover, the presence of key market players and ongoing research into innovative therapies are expected to further enhance market dynamics in the region.

Key players in the market

Some of the key players profiled in the Thyroid Gland Disorders Treatment Market include Abbott Laboratories, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Boehringer Ingelheim GmbH, Amgen Inc., Takeda Pharmaceutical Company Limited, ThyroSafe, LLC, Hormone Health Network, Zydus Cadila, Mylan N.V., Hikma Pharmaceuticals PLC, Endo International PLC, Genzyme Corporation and Roche Holding AG.

Key Developments:

In September 2024, Abbott announced collaboration with the DoD to develop and distribute a rapid COVID-19 test that provides results in under 30 minutes, aiming to enhance testing capabilities for military personnel.

In August 2024, Abbott acquired Walk Vascular, a company specializing in advanced vascular access solutions, enhancing its product portfolio in medical devices for vascular access.

In April 2024, Abbott formed a joint venture with Axiom Health to create digital health solutions that integrate diagnostics with data analytics to improve patient outcomes in chronic disease management.

Type of Disorders Covered:

  • Hypothyroidism
  • Hyperthyroidism
  • Goiter
  • Thyroid Cancer
  • Hashimoto's Thyroiditis
  • Graves' Disease
  • Thyroid Nodules
  • Other Type of Disorders

Treatment Types Covered:

  • Medications
  • Surgery
  • Radiofrequency Ablation
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Injectable
  • Topical
  • Other Route of Administrations

Drug Types Covered:

  • Levothyroxine
  • Liothyronine
  • Propylthiouracil
  • Imidazole-Based Compounds
  • Other Drug Types

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Clinics
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Thyroid Gland Disorders Treatment Market, By Type of Disorder

  • 5.1 Introduction
  • 5.2 Hypothyroidism
  • 5.3 Hyperthyroidism
  • 5.4 Goiter
  • 5.5 Thyroid Cancer
  • 5.6 Hashimoto's Thyroiditis
  • 5.7 Graves' Disease
  • 5.8 Thyroid Nodules
  • 5.9 Other Type of Disorders

6 Global Thyroid Gland Disorders Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Medications
    • 6.2.1 Hormone Replacement Therapy
    • 6.2.2 Antithyroid Drugs
    • 6.2.3 Radioactive Iodine Therapy
  • 6.3 Surgery
    • 6.3.1 Thyroidectomy
    • 6.3.2 Lobectomy
  • 6.4 Radiofrequency Ablation
  • 6.5 Other Treatment Types
    • 6.5.1 Nutritional Supplements
    • 6.5.2 Herbal Remedies

7 Global Thyroid Gland Disorders Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Topical
  • 7.5 Other Route of Administrations

8 Global Thyroid Gland Disorders Treatment Market, By Drug Type

  • 8.1 Introduction
  • 8.2 Levothyroxine
  • 8.3 Liothyronine
  • 8.4 Propylthiouracil
  • 8.5 Imidazole-Based Compounds
  • 8.6 Other Drug Types

9 Global Thyroid Gland Disorders Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Clinics
  • 8.6 Other Distribution Channels

10 Global Thyroid Gland Disorders Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 AstraZeneca PLC
  • 12.3 Bristol-Myers Squibb Company
  • 12.4 Eli Lilly and Company
  • 12.5 GlaxoSmithKline PLC
  • 12.6 Merck & Co., Inc.
  • 12.7 Novartis AG
  • 12.8 Pfizer Inc.
  • 12.9 Sanofi S.A.
  • 12.10 Boehringer Ingelheim GmbH
  • 12.11 Amgen Inc.
  • 12.12 Takeda Pharmaceutical Company Limited
  • 12.13 ThyroSafe, LLC
  • 12.14 Hormone Health Network
  • 12.15 Zydus Cadila
  • 12.16 Mylan N.V.
  • 12.17 Hikma Pharmaceuticals PLC
  • 12.18 Endo International PLC
  • 12.19 Genzyme Corporatio
  • 12.20 Roche Holding AG

List of Tables

  • Table 1 Global Thyroid Gland Disorders Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2022-2030) ($MN)
  • Table 3 Global Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2022-2030) ($MN)
  • Table 4 Global Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2022-2030) ($MN)
  • Table 5 Global Thyroid Gland Disorders Treatment Market Outlook, By Goiter (2022-2030) ($MN)
  • Table 6 Global Thyroid Gland Disorders Treatment Market Outlook, By Thyroid Cancer (2022-2030) ($MN)
  • Table 7 Global Thyroid Gland Disorders Treatment Market Outlook, By Hashimoto's Thyroiditis (2022-2030) ($MN)
  • Table 8 Global Thyroid Gland Disorders Treatment Market Outlook, By Graves' Disease (2022-2030) ($MN)
  • Table 9 Global Thyroid Gland Disorders Treatment Market Outlook, By Thyroid Nodules (2022-2030) ($MN)
  • Table 10 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Type of Disorders (2022-2030) ($MN)
  • Table 11 Global Thyroid Gland Disorders Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 12 Global Thyroid Gland Disorders Treatment Market Outlook, By Medications (2022-2030) ($MN)
  • Table 13 Global Thyroid Gland Disorders Treatment Market Outlook, By Hormone Replacement Therapy (2022-2030) ($MN)
  • Table 14 Global Thyroid Gland Disorders Treatment Market Outlook, By Antithyroid Drugs (2022-2030) ($MN)
  • Table 15 Global Thyroid Gland Disorders Treatment Market Outlook, By Radioactive Iodine Therapy (2022-2030) ($MN)
  • Table 16 Global Thyroid Gland Disorders Treatment Market Outlook, By Surgery (2022-2030) ($MN)
  • Table 17 Global Thyroid Gland Disorders Treatment Market Outlook, By Thyroidectomy (2022-2030) ($MN)
  • Table 18 Global Thyroid Gland Disorders Treatment Market Outlook, By Lobectomy (2022-2030) ($MN)
  • Table 19 Global Thyroid Gland Disorders Treatment Market Outlook, By Radiofrequency Ablation (2022-2030) ($MN)
  • Table 20 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 21 Global Thyroid Gland Disorders Treatment Market Outlook, By Nutritional Supplements (2022-2030) ($MN)
  • Table 22 Global Thyroid Gland Disorders Treatment Market Outlook, By Herbal Remedies (2022-2030) ($MN)
  • Table 23 Global Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 24 Global Thyroid Gland Disorders Treatment Market Outlook, By Oral (2022-2030) ($MN)
  • Table 25 Global Thyroid Gland Disorders Treatment Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 26 Global Thyroid Gland Disorders Treatment Market Outlook, By Topical (2022-2030) ($MN)
  • Table 27 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Route of Administrations (2022-2030) ($MN)
  • Table 28 Global Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 29 Global Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2022-2030) ($MN)
  • Table 30 Global Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2022-2030) ($MN)
  • Table 31 Global Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2022-2030) ($MN)
  • Table 32 Global Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2022-2030) ($MN)
  • Table 33 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 34 Global Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 35 Global Thyroid Gland Disorders Treatment Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 36 Global Thyroid Gland Disorders Treatment Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 37 Global Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 38 Global Thyroid Gland Disorders Treatment Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 39 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.